Supplement Figure 2 from MYBL2 Drives Prostate Cancer Plasticity: Inhibiting Its Transcriptional Target CDK2 for RB1-Deficient Neuroendocrine Prostate Cancer

Supplement Figure 2. A. SKO, DKO, and PPKO were cultured as 3-dimensional spheroids and treated with the indicated concentrations of the CDK2 inhibitor - BGG463 over 72 hours. Cell growth was determined by CellTiter-Glo luminescent cell viability assay. B. Western blot analysis for Cdk2, Cdk5, and Vinculin following DKO and PPKO were treated with the indicated concentration of the CDK2 PROTAC - CPS2. Full western blot membranes for C) CDK2, D) CDK5, and E) vinculin.